116 related articles for article (PubMed ID: 36938720)
1. The role of HMGCR expression in combination therapy of simvastatin and FAC treated locally advanced breast cancer patients.
Yulian ED; Siregar NC; Sudijono B; Hwei LRY
Breast Dis; 2023; 42(1):73-83. PubMed ID: 36938720
[TBL] [Abstract][Full Text] [Related]
2. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
[TBL] [Abstract][Full Text] [Related]
3. Combination of Simvastatin and FAC Improves Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Yulian ED; Siregar NC; Bajuadji
Cancer Res Treat; 2021 Oct; 53(4):1072-1083. PubMed ID: 33705623
[TBL] [Abstract][Full Text] [Related]
4. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
[TBL] [Abstract][Full Text] [Related]
5. Statin use, HMGCR expression, and breast cancer survival - The Malmö Diet and Cancer Study.
Bjarnadottir O; Feldt M; Inasu M; Bendahl PO; Elebro K; Kimbung S; Borgquist S
Sci Rep; 2020 Jan; 10(1):558. PubMed ID: 31953433
[TBL] [Abstract][Full Text] [Related]
6. Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase.
Göbel A; Pählig S; Motz A; Breining D; Traikov S; Hofbauer LC; Rachner TD
Biochem Biophys Res Commun; 2024 May; 710():149841. PubMed ID: 38588613
[TBL] [Abstract][Full Text] [Related]
7. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
Butt S; Butt T; Jirström K; Hartman L; Amini RM; Zhou W; Wärnberg F; Borgquist S
Ann Surg Oncol; 2014 Sep; 21(9):2911-9. PubMed ID: 24777857
[TBL] [Abstract][Full Text] [Related]
8. Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells.
Dewidar SA; Hamdy O; Soliman MM; El Gayar AM; El-Mesery M
Med Oncol; 2023 Dec; 41(1):7. PubMed ID: 38051378
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
[TBL] [Abstract][Full Text] [Related]
10. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin.
Mangravite LM; Medina MW; Cui J; Pressman S; Smith JD; Rieder MJ; Guo X; Nickerson DA; Rotter JI; Krauss RM
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1485-92. PubMed ID: 20413733
[TBL] [Abstract][Full Text] [Related]
11. Role of hydroxymethylglutharyl-coenzyme A reductase in the induction of stem-like states in breast cancer.
Marks MP; Giménez CA; Isaja L; Vera MB; Borzone FR; Pereyra-Bonnet F; Romorini L; Videla-Richardson GA; Chasseing NA; Calvo JC; Vellón L
J Cancer Res Clin Oncol; 2024 Feb; 150(2):106. PubMed ID: 38418798
[TBL] [Abstract][Full Text] [Related]
12. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin.
Medina MW; Gao F; Ruan W; Rotter JI; Krauss RM
Circulation; 2008 Jul; 118(4):355-62. PubMed ID: 18559695
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol potentiates effect of simvastatin on inhibition of mevalonate pathway in human endometrial stromal cells.
Villanueva JA; Sokalska A; Cress AB; Ortega I; Bruner-Tran KL; Osteen KG; Duleba AJ
J Clin Endocrinol Metab; 2013 Mar; 98(3):E455-62. PubMed ID: 23386644
[TBL] [Abstract][Full Text] [Related]
14. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
[TBL] [Abstract][Full Text] [Related]
15. Statin resistance in Candida glabrata.
Subhan M; Faryal R; Macreadie I
Biotechnol Lett; 2018 Oct; 40(9-10):1389-1394. PubMed ID: 30054755
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial comparing the efficacy of daily and every other day atorvastatin therapy and its correlation with serum hydroxymethylglutaryl-CoA reductase enzyme levels in naïve dyslipidemic patients.
Kumar M; Rehan HS; Puri R; Yadav M; Gupta LK
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S64-S67. PubMed ID: 30595323
[TBL] [Abstract][Full Text] [Related]
17. Explication of interactions between HMGCR isoform 2 and various statins through In silico modeling and docking.
Karthik MV; Satya Deepak MV; Shukla P
Comput Biol Med; 2012 Feb; 42(2):156-63. PubMed ID: 22177940
[TBL] [Abstract][Full Text] [Related]
18. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
[TBL] [Abstract][Full Text] [Related]
19. HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism.
Yu CY; Theusch E; Lo K; Mangravite LM; Naidoo D; Kutilova M; Medina MW
Hum Mol Genet; 2014 Jan; 23(2):319-32. PubMed ID: 24001602
[TBL] [Abstract][Full Text] [Related]
20. The role of HMGCR alternative splicing in statin efficacy.
Medina MW; Krauss RM
Trends Cardiovasc Med; 2009 Jul; 19(5):173-7. PubMed ID: 20005478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
